<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152943">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781390</url>
  </required_header>
  <id_info>
    <org_study_id>ANG.AMI-IC001</org_study_id>
    <nct_id>NCT01781390</nct_id>
  </id_info>
  <brief_title>Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction</brief_title>
  <acronym>AMICI</acronym>
  <official_title>A Prospective, Double Blind, Randomized, Placebo-controlled Clinical Trial of Intracoronary Infusion of Immunoselected, Bone Marrow-derived Stro3 Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angioblast Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mesoblast, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mesoblast, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Angioblast Systems</source>
  <oversight_info>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>New Zealand: Medsafe</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomized, placebo controlled study that will enroll 225 subjects
      with de novo anterior myocardial infarction due to a lesion of the left anterior descending
      coronary artery undergoing PCI.  Eligible subjects will be enrolled and undergo
      revascularization of the culprit LAD followed by an intracoronary (IC) delivery of the
      assigned treatment, infused into the stented culprit artery. The study will determine the
      safety and feasibility of the IC infusion of investigational MPCs in this patient
      population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Frequency of the total major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Occurrence of MACCE events including cardiac death, myocardial infarction, target vessel revascularization, stroke, new or worsening congestive heart failure during index hospitalization and cardiac hospitalizations due to congestive heart failure.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>12.5M MPCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25M MPCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25M Mesenchymal Precursor Cell (MPC) administered via IC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo via IC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mesenchymal Precursor Cells (MPC)</intervention_name>
    <arm_group_label>12.5M MPCs</arm_group_label>
    <arm_group_label>25M MPCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical symptoms consistent with AMI (pain, etc.) from a minimum of 2 to maximum of
             12 hours from onset of symptoms to percutaneous coronary intervention (PCI)

          -  De Novo anterior Acute Myocardial Infarct (AMI)

          -  Successful revascularization of the culprit lesion

          -  Female of child bearing potential willing to use contraception and must have negative
             pregnancy test upon screening

        Key Exclusion Criteria:

          -  Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF)

          -  Significant valvular disease

          -  Need for staged treatment of coronary artery disease (CAD), or other interventional
             or surgical procedure to treat heart disease (planned or scheduled)

          -  Cardiogenic shock or hemodynamic instability within 24 hours of randomization

          -  Prior PCI to LAD

          -  Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other
             contra-indication for cardiac MRI

          -  Prior or current participation in any stem cell study or any other investigational
             trial in the past 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Adams, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Duckers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Priya Raina</last_name>
    <phone>212 993 7925</phone>
    <email>priya.raina@mesoblast.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Cohen</last_name>
    <phone>212 993 7922</phone>
    <email>rebecca.cohen@mesoblast.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ananth Prasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sukumaran Thambar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gishel New</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Northern Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Van Gaal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michelle Ammerer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shetty Sharad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel Klinische</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Danny Schoors</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Kastrup</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>2214</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Elliot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerry Devlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 29, 2013</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>STEMI</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>AMI</keyword>
  <keyword>Stem Cells</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
